Literature DB >> 29031784

Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.

Xiaorui Yao1, Fan Xia2, Waijiao Tang3, Chunxin Xiao3, Miaoting Yang3, Benjie Zhou4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Hugan Qingzhi tablet (HQT), a traditional Chinese medicine formula has been adopted for preventing and treating nonalcoholic fatty liver disease (NAFLD). AIM: In order to explore the anti-NAFLD mechanisms of HQT, iTRAQ-based proteomic was employed to investigate the expression profiles of proteins in NAFLD rats induced by high-fat diet after HQT treatment.
MATERIALS AND METHODS: The NAFLD rat model was administrated with high-fat diet (HFD) for 12weeks. HQT was administrated in a daily basis to the HFD groups. Biochemical markers, liver histology, pro-inflammatory cytokines, and oxidative stress/antioxidant biomarkers were assayed to evaluate HQT effects in HFD-induced NAFLD rats. Furthermore, the combined strategy of iTRAQ labeling with strong cation exchange-non-liquid chromatography-tandem mass spectrometry (SCX-non-LC-MS/MS) analysis were employed to explore the mechanisms of HQT's protective effect against NAFLD in rats. Western blotting was performed to verify the proteomic results.
RESULTS: The histopathologic characteristics and biochemical data showed that HQT exhibited protective effects on HFD-induced NAFLD rats. After being analyzed by the combined strategy of iTRAQ with LC-MS/MS and subsequent investigation, we identified 275 differentially expressed proteins in the HFD group, compared to the control; 207 altered proteins in the HQT high dose + HFD group, compared to the HFD group; and 316 altered proteins in the HQT high dose + HFD group, compared to the control. Based on the Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway mapping, the conclusion has reached that several pathways including microbial metabolism in diverse environments, fatty acid metabolism, inflammatory response, oxidative stress, bile secretion, and peroxisome proliferator activated receptor (PPAR) signaling pathway were closely related to the effects of HQT in HFD-induced NAFLD in rats. Furthermore, several differentially expressed proteins, including phytanoyl-CoA 2-hydroxylase (PHYH), acyl-CoA synthetase 1 long chain (ACSL1), hemopexin, Alpha-1-acid glycoprotein (ORM1), fatty acid binding protein 4 (FABP4), soluble sulphotransferase 2a1 (Sult2a1), and argininosuccinate synthase 1 (ASS1) were verified by the western blotting analysis and these results were consistent with the data obtained from the proteomics analysis.
CONCLUSIONS: Our results not only confirm that Hugan Qingzhi exhibits a significant protective effect in HFD-induced NAFLD rats but also provide a better understanding for the treatments of NAFLD.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hugan Qingzhi tablet (HQT); Isobaric tags for relative and absolute quantitation (iTRAQ); Nonalcoholic fatty liver disease (NAFLD); Proteomic; Traditional Chinese medicine

Mesh:

Substances:

Year:  2017        PMID: 29031784     DOI: 10.1016/j.jep.2017.09.016

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  8 in total

1.  [Effects of sera of rats fed with Huganqingzhi tablets on endoplasmic reticulum stress in a HepG2 cell model of nonalcoholic fatty liver disease].

Authors:  Miaoting Yang; Zhijuan Chen; Chunxin Xiao; Waijiao Tang; Beijie Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Data for iTRAQ-based quantification of the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats.

Authors:  Xiaorui Yao; Fan Xia; Waijiao Tang; Chunxin Xiao; Miaoting Yang; Benjie Zhou
Journal:  Data Brief       Date:  2017-10-16

3.  Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ.

Authors:  Miaoting Yang; Zhijuan Chen; Shijian Xiang; Fan Xia; Waijiao Tang; Xiaorui Yao; Benjie Zhou
Journal:  BMC Complement Med Ther       Date:  2020-12-11

4.  Discovery of Quality Markers in Hugan Qingzhi Formula by Integrating a Lipid-Lowering Bioassay with UHPLC-QQQ-MS/MS.

Authors:  Fan He; Chun-Xin Xiao; Can-Jian Wang; Jie Liang; Qi-Qing Cheng; Li Zhang; Ben-Jie Zhou; Hua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-12       Impact factor: 2.629

5.  Proteomics for studying the effects of L. rhamnosus LV108 against non-alcoholic fatty liver disease in rats.

Authors:  Hengxian Qu; Hongbo Yu; Ruixia Gu; Dawei Chen; Xia Chen; Yingping Huang; Wenbo Xi; Yujun Huang
Journal:  RSC Adv       Date:  2018-11-15       Impact factor: 4.036

6.  Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.

Authors:  Waijiao Tang; Xiaorui Yao; Fan Xia; Miaoting Yang; Zhijuan Chen; Benjie Zhou; Qiang Liu
Journal:  Oxid Med Cell Longev       Date:  2018-12-23       Impact factor: 6.543

7.  Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis.

Authors:  Hong Xu; Gao-Feng Chen; Yu-Shui Ma; Hong-Wei Zhang; Yang Zhou; Guang-Hui Liu; Dong-Ya Chen; Jian Ping; Yi-Hui Liu; Xin Mou; Da Fu
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

Review 8.  Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.

Authors:  Juan Moreno-Vedia; Josefa Girona; Daiana Ibarretxe; Lluís Masana; Ricardo Rodríguez-Calvo
Journal:  Biomedicines       Date:  2022-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.